When depression has not responded to multiple medications, the next recommendation can feel both hopeful and intimidating. Many patients ask the same question: how does Spravato work, and why is it different from a standard antidepressant? The short answer is that Spravato works on different brain pathways than most traditional medications, and for some people with treatment-resistant depression, that difference matters.
Spravato is the brand name for esketamine, an FDA-approved nasal spray used under medical supervision for adults with treatment-resistant depression and, in certain cases, major depressive disorder with acute suicidal thoughts or behaviors. Unlike many common antidepressants that mainly affect serotonin, norepinephrine, or dopamine over time, Spravato targets the brain’s glutamate system. That shift in mechanism is a big reason it has become an important option in interventional psychiatry.
How does Spravato work in the brain?
Spravato acts on the NMDA receptor, which is part of the glutamate system. Glutamate is the brain’s main excitatory neurotransmitter and plays a major role in learning, memory, and the way brain cells communicate. Esketamine blocks NMDA receptors in a way that appears to trigger a cascade of changes in brain signaling.
That cascade is believed to increase synaptic plasticity, which is the brain’s ability to strengthen and rebuild connections between nerve cells. In depression, especially long-standing or treatment-resistant depression, those communication networks can become less flexible and less efficient. Spravato may help restore activity in circuits involved in mood, motivation, and emotional regulation.
This is one reason people often hear that Spravato is different from a typical antidepressant. Traditional antidepressants can be very effective, but they often take several weeks to produce meaningful improvement. Spravato works through a different pathway, and some patients notice changes sooner. That does not mean it works immediately for everyone, or that every response is dramatic. It means the biology behind the treatment is distinct.
Why Spravato may help when other antidepressants have not
Treatment-resistant depression usually means a person has not had enough improvement after trying at least two antidepressants at adequate doses and for an adequate length of time. That experience is common, and it does not mean the depression is untreatable. It often means a different strategy is needed.
For some patients, the issue is not simply low serotonin or norepinephrine activity. Depression is more complex than any single chemical imbalance. Brain inflammation, stress response systems, neural connectivity, trauma history, sleep disruption, and co-occurring anxiety can all shape how depression shows up and how well someone responds to treatment.
Because Spravato affects glutamate signaling and may support new neural connections, it offers an alternative route when the usual medication approaches have not been enough. It is not a first-line treatment for everyone, but it can be a meaningful option for people who feel stuck after multiple medication trials.
What treatment with Spravato actually involves
One of the most important things to know is that Spravato is not taken at home like a regular prescription. It is administered in a certified medical setting under supervision because the medication can temporarily affect blood pressure, alertness, perception, and coordination.
At a treatment visit, the nasal spray is self-administered under the guidance of a trained clinician. After dosing, patients stay in the office for monitoring, typically for at least two hours. During that time, the care team watches for side effects and helps ensure the patient remains safe and comfortable until they are ready to leave with arranged transportation.
Spravato is also not used as a stand-alone treatment for treatment-resistant depression. It is prescribed along with an oral antidepressant. The schedule usually begins with a more frequent induction phase, often twice weekly, followed by a maintenance phase that may shift to weekly or every other week depending on clinical response.
That structure matters. The goal is not just to provide a single intervention, but to build a treatment plan that supports more stable, lasting improvement.
What does Spravato feel like during treatment?
The experience varies from person to person. Some people feel relaxed, detached, or mildly lightheaded. Others notice temporary dissociation, which can feel like being somewhat disconnected from thoughts, surroundings, or the passage of time. Some patients feel sleepy, while others simply feel mentally quieter than usual.
These effects are usually temporary and are part of the reason monitoring is required after each treatment. For many patients, the session is manageable, especially when they know what to expect and are in a calm, medically supervised environment.
Not every sensation during treatment predicts whether the medication will help. Some people have noticeable temporary effects and improve. Others have mild session experiences but still benefit over time. Response is judged by how depressive symptoms change across days and weeks, not by how unusual the treatment visit feels.
How quickly does Spravato start working?
This is one of the most common and understandable questions. Some patients notice improvement within hours to days, especially in areas like mood heaviness, hopelessness, or emotional numbness. Others improve more gradually across the first several weeks of treatment.
There is no guaranteed timeline. Depression is highly individual, and response depends on several factors, including symptom severity, coexisting psychiatric conditions, stressors, sleep, substance use, medical history, and whether the diagnosis is fully accurate. A fast start can happen, but treatment should still be viewed as a process rather than a one-time fix.
Who may be a good candidate?
Spravato is generally considered for adults with treatment-resistant depression and in some cases for adults with major depressive disorder and acute suicidal thoughts or behaviors. A careful psychiatric evaluation is essential because the treatment is not appropriate for everyone.
A strong candidate is often someone who has tried standard antidepressant approaches without enough relief and is looking for evidence-based alternatives in a structured setting. At the same time, there are situations where extra caution is needed, such as uncontrolled high blood pressure, certain vascular conditions, active substance use concerns, or a history of psychotic symptoms. This does not automatically rule treatment out in every case, but it does mean the decision should be individualized.
The broader point is that eligibility is based on diagnosis, history, safety factors, and treatment goals, not just on interest in trying something new.
Benefits, limits, and what to expect over time
The promise of Spravato is real, but so are the trade-offs. For the right patient, it can offer meaningful relief when other treatments have failed. It may reduce depressive symptoms, improve function, and help restore a sense of clarity and hope. For some people, it creates enough improvement to re-engage with therapy, work, relationships, and daily life.
But Spravato is not a cure-all. Some patients respond strongly, some partially, and some do not respond enough to continue. The time commitment is significant, especially early on, because treatment requires in-office monitoring. Side effects such as nausea, dizziness, sedation, temporary increases in blood pressure, and dissociation can occur. Cost and insurance coverage can also shape access.
This is why a thoughtful treatment plan matters. In many cases, the best results come when Spravato is part of a larger strategy that may include medication management, psychotherapy, sleep support, lifestyle changes, and in some cases other interventional treatments.
How does Spravato work compared with TMS or standard medication?
Patients exploring advanced depression treatment often compare Spravato with oral antidepressants or Transcranial Magnetic Stimulation, also called TMS. These treatments are not interchangeable, but they can all be valuable depending on the clinical picture.
Oral antidepressants are often the first step because they are widely used, accessible, and effective for many people. TMS uses magnetic pulses to stimulate specific brain regions involved in mood regulation and does not involve systemic medication. Spravato, by contrast, is a medication-based interventional treatment that works through glutamate-related pathways and is given under supervision.
Which option makes the most sense depends on prior treatment history, symptom profile, medical factors, patient preference, scheduling realities, and how quickly symptom relief is needed. At Brainiac Behavioral Health, Spravato treatment is available in Orange and Anaheim Hills, giving patients in Orange County access to a structured, evidence-based option when traditional approaches have not been enough.
If you have been living with persistent depression, asking better questions is not a sign of doubt. It is a sign that you are still looking for a path forward. Sometimes the next step is not more of the same, but a treatment that reaches the brain in a different way and opens the door to meaningful change.